Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

25.94 -0.81 (-3.03%)
Streaming Delayed Price Updated: 3:35 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback
 
Via Benzinga
Topics Earnings
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug
Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results. 
Via Benzinga
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug
Via Stocktwits
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Why Zai Lab (ZLAB) Stock Is Trading Higher
Zai Lab shares are trading higher by 4% during Friday's session. The company priced a $200 million public offering. 
Via Benzinga
Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects
Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected later. 
Via Benzinga
ZAI LAB LTD-ADR (NASDAQ:ZLAB) – A High-Growth Biotech Stock Meeting Minervini’s Criteria
ZAI LAB LTD-ADR (NASDAQ:ZLAB) is a high-growth biotech stock meeting Minervini’s Trend Template with strong revenue growth, technical strength, and sector leadership. 
Via Chartmill
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Guidewire Software Posts Upbeat Q3 Results, Joins Yext, REV Group And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Wednesday's session: gap up and gap down stocks
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial. 
Via Benzinga
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?
Top mid-cap performers last week: Webull Corp, Hertz Global, Metsera Inc, Vista Energy, Certara Inc, Sibanye-Stillwater, Banco Macro, Grupo Financiero Galicia, Banco BBVA Argentina, Recursion... 
Via Benzinga
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Why ZAI LAB LTD-ADR (NASDAQ:ZLAB) could fit Mark Minervini’s high-growth criteria
A fundamental and technical analysis of (NASDAQ:ZLAB): Why the high growth investor may take a look at ZAI LAB LTD-ADR (NASDAQ:ZLAB). 
Via Chartmill
No Fear And No Panic After A 10% Correction = No Bottom
In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off. 
Via Talk Markets
Topics Stocks / Equities
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
NovoCure Q4 EPS Misses, Revenue Matches
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
Via The Motley Fool
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. 
Via Benzinga
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results
The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells. 
Via Investor's Business Daily
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.